Olanzapine Glenmark Europe 20 mg orodispersible tablets

Olanzapine Glenmark Europe belongs to a group of medicines called antipsychotics.

Olanzapine Glenmark Europe is used to treat a disease with symptoms such as hearing, seeing or sensing things which are not there, mistaken beliefs, unusual suspiciousness, and becoming withdrawn. People with this disease may also feel depressed, anxious or tense.

Olanzapine Glenmark Europe is used to treat a condition with symptoms such as feeling "high", having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability. It is also a mood stabiliser that prevents further occurrences of the disabling high and low (depressed) extremes of mood associated with this condition.

Do not take Olanzapine Glenmark Europe

• if you are allergic (hypersensitive) to olanzapine or any of the other ingredients of Olanzapine Glenmark Europe . An allergic reaction may be recognised as a rash, itching, a swollen face, swollen lips or shortness of breath. If this has happened to you, tell your doctor.
• if you have been previously diagnosed with eye problems such as certain kinds of glaucoma (increased pressure in the eye).

Take special care with Olanzapine Glenmark Europe

• Medicines of this type may cause unusual movements mainly of the face or tongue. If this happens after you have been given Olanzapine Glenmark Europe, tell your doctor.
• Very rarely, medicines of this type cause a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness. If this happens, contact your doctor at once.
• The use of Olanzapine Glenmark Europe in elderly patients with dementia is not recommended as it may have serious side effects. If you suffer from any of the following illnesses tell your doctor as soon as possible:
• Diabetes
• Heart disease
• Liver or kidney disease
• Parkinson?s disease
• Epilepsy
• Prostate problems
• A blocked intestine (Paralytic ileus)
• Blood disorders
• Stroke or ?mini? stroke (temporary symptoms of stroke)

If you suffer from dementia, you or your carer/relative should tell your doctor if you have ever had a stroke or ?mini? stroke.

As a routine precaution, if you are over 65 years your blood pressure may be monitored by your doctor.

Olanzapine Glenmark Europe is not for patients who are under 18 years..

Taking other medicines
Only take other medicines while you are on Olanzapine Glenmark Europe if your doctor tells you that you can. You might feel drowsy if Olanzapine Glenmark Europe is taken in combination with antidepressants or medicines taken for anxiety or to help you sleep (tranquillisers).

You should tell your doctor if you are taking fluvoxamine (an antidepressant), or ciprofloxacin (an antibiotic), as it may be necessary to change your Olanzapine Glenmark Europe dose.

Please tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. Especially tell your doctor if you are taking medicines for Parkinson?s disease.

Taking Olanzapine Glenmark Europewith food and drink
Do not drink any alcohol if you have been given Olanzapine Glenmark Europe as Olanzapine Glenmark Europe and alcohol together may make you feel drowsy.

Pregnancy and breast-feeding

Tell your doctor as soon as possible if you are pregnant or think you may be pregnant. You should not take this medicine when pregnant, unless you have discussed this with your doctor. You should not be given this medicine when breast-feeding, as small amounts of Olanzapine Glenmark Europe can pass into breast milk.

Driving and using machines

There is a risk of feeling drowsy when you are given Olanzapine Glenmark Europe. If this happens do not drive or use any tools or machines. Tell your doctor.

Important information about some of the ingredients of Olanzapine Glenmark Europe Olanzapine Glenmark Europe contains a source of phenylalanine. This may be harmful for people with phenylketonuria.

Always take Olanzapine Glenmark Europe exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.

doctor will tell you how many Olanzapine Glenmark Europe orodispersible tablets to take and how long you should continue to take them. The daily dose of Olanzapine Glenmark Europe is between 5 and 20 mg. Consult your doctor if your symptoms return but do not stop taking Olanzapine Glenmark Europe unless your doctor tells you to.

You should take your Olanzapine Glenmark Europe orodispersible tablets once a day following the advice of your doctor. Try to take your tablets at the same time each day. It does not matter whether you take them with or without food. Olanzapine Glenmark Europe orodispersible tablets are for oral use. Put the tablet in your mouth. It will dissolve directly in your mouth, so that it can be easily swallowed. You can also place the tablet in a full glass or cup of water or other suitable beverage (orange juice, apple juice, milk or coffee) and stir. Drink it straightaway.

If you take more Olanzapine Glenmark Europethan you should
Patients who have taken more Olanzapine Glenmark Europe than they should, have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness. Other symptoms may be: acute confusion, seizures (epilepsy), coma, a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness, slowing of the breathing rate, aspiration, high blood pressure or low blood pressure, abnormal rhythms of the heart. Contact your doctor or hospital straight away. Show the doctor your pack of tablets.

If you forget to take Olanzapine Glenmark Europe
Take your tablets as soon as you remember. Do not take two doses in one day.

If you stop taking Olanzapine Glenmark Europe

Do not stop taking your tablets just because you feel better. It is important that you carry on taking Olanzapine Glenmark Europe for as long as your doctor tells you.

If you suddenly stop taking Olanzapine Glenmark Europe, symptoms such as sweating, unable to sleep, tremor, anxiety or nausea and vomiting might occur. Your doctor may suggest you to reduce the dose gradually before stopping treatment.
If you have any further questions on the use of this product, ask your doctor or pharmacist.

Like all medicines, Olanzapine Glenmark Europe can cause side effects, although not everybody gets them.
Very common side effects: affect 1 user in 10

• Weight gain
• Sleepiness
• Increases in the levels of prolactin in the blood.

Common side effects: affect 1 to 10 users in 100

• Changes in the levels of some blood cells and circulating fats.
• Increases in the level of sugars in the blood and urine.
• Feeling more hungry.
• Dizziness.
• Restlessness.
• Tremor.
• Muscle stiffness or spasm (including eye movements).
• Problems with speech.
• Unusual movement (especially of the face and tongue).
• Constipation.
• Dry mouth.
• Rash.
• Loss of strength.
• Extreme tiredness.
• Water retention leading to swelling of the hands, ankles or feet.
• In early stages of treatment, some people may feel dizzy or faint (with a slow heart rate), especially when getting up from a lying or sitting position. This will usually pass on its own but if it does not, tell your doctor.
• Sexual dysfunctions such as decreased libido in males and females or erectile dysfunction in males.

Uncommon side effects: affect 1 to 10 users in 1,000

• Slow heart rate.
• Make you sensitive to sunlight.
• Urinary incontinence.
• Hair loss.
• Absence or decrease in menstrual periods.
• Changes in breasts in males and females such as an abnormal production of breast milk or abnormal growth.

Other possible side effects: frequency cannot be estimated from the available data.

• Allergic reaction (e.g. swelling in the mouth and throat, itching, rash).
• Diabetes or the worsening of diabetes, occasionally associated with ketoacidosis (ketones in the blood and urine) or coma.
• Lowering of normal body temperature.
• Seizures, usually associated with a history of seizures (epilepsy).
• Combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness.
• Spasms of the muscle of the eye causing rolling movement of the eye.
• Abnormal rhythms of the heart.
• Sudden unexplained death.
• Blood clots such as deep venous thrombosis of the leg or blood clot on the lung.
• Inflammation of the pancreas causing severe stomach pain, fever and sickness.
• Liver disease appearing as yellowing of the skin and white parts of the eyes.
• Muscle disease presenting as unexplained aches and pains.
• Difficulty in passing urine.
• Prolonged and/or painful erection.

While taking olanzapine, elderly patients with dementia may suffer from stroke, pneumonia, urinary incontinence, falls, extreme tiredness, visual hallucinations, a rise in body temperature, redness of the skin and have trouble walking. Some fatal cases have been reported in this particular group of patients.

In patients with Parkinson?s disease Olanzapine Glenmark Europe may worsen the symptoms

Rarely women taking medicines of this type for a long time have started to secrete milk and have missed periods or had irregular periods. If this persists tell your doctor. Very rarely babies born to mothers who have taken olanzapine in the last stage of pregnancy (3rd trimester) may have tremors, be sleepy or drowsy.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor.

Keep out of the reach and sight of children

Do not use Olanzapine Glenmark Europe after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.

Store below 30°C.

Please return left over medicine to your pharmacist. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

What Olanzapine Glenmark Europecontains

• The active substance is olanzapine
• Each Olanzapine Glenmark Europe orodispersible tablet contains, 5 mg, 10 mg, 15 mg, or 20 mg olanzapine
• The other ingredients are mannitol (E 421), microcrystalline cellulose, aspartame (E 951), crospovidone, magnesium stearate

What Olanzapine Glenmark Europelooks like and contents of the pack

Olanzapine Glenmark Europe 5mg is supplied as :
yellow coloured circular flat bevelled edge orodispersible tablets with ?2? debossed on one side. Olanzapine Glenmark Europe 10 mg:
yellow coloured circular flat bevelled edge orodispersible tablets with ?OL? debossed on one side and ?4? debossed on other side.
Olanzapine Glenmark Europe 15 mg:
yellow coloured circular flat bevelled edge orodispersible tablets with ?OL? debossed on one side and ?5? debossed on other side.
Olanzapine Glenmark Europe 20 mg:
yellow coloured circular flat bevelled edge orodispersible tablets with ?OL? debossed on one side and ?6? debossed on other side.

Olanzapine Glenmark Europe 5 mg, 10 mg, 15 mg and 20 mg are available in aluminium foil blisters of 28, 56, and 70 orodispersible tablets

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Glenmark Generics (Europe) Limited
Laxmi House
2-B Draycott Avenue
Kenton

Harrow
Middlesex
HA3 OBU.
United Kingdom

Manufacturer

Glenmark Pharmaceuticals s.r.o.
City Tower, Hv-zdova 1716/2b, 140 78 Praha 4
Czech Republic

This leaflet was last approved in {MM/YYYY}.